NPH insulin: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{short description|A type of insulin used to manage blood sugar levels in diabetes}} | |||
[[File:Insulin&Syringe.JPG|thumb|right|NPH insulin is often administered using a syringe.]] | |||
NPH insulin is | '''NPH insulin''' (Neutral Protamine Hagedorn insulin) is an intermediate-acting insulin used in the management of [[diabetes mellitus]]. It is designed to help control blood sugar levels in individuals with [[type 1 diabetes]] and [[type 2 diabetes]]. | ||
== | ==History== | ||
NPH insulin was developed in the 1940s by Hans Christian Hagedorn and B. Norman Jensen. The addition of [[protamine]], a protein, to insulin extends its duration of action, making it suitable for basal insulin needs. | |||
NPH insulin is | ==Pharmacology== | ||
NPH insulin is an intermediate-acting insulin with an onset of action of 1 to 2 hours, a peak effect occurring 4 to 12 hours after administration, and a duration of action of approximately 12 to 18 hours. It is typically administered subcutaneously. | |||
== | ==Mechanism of Action== | ||
NPH insulin works by facilitating the uptake of glucose into cells, particularly in the liver, muscle, and fat tissue, thereby lowering blood glucose levels. The protamine component delays the absorption of insulin, providing a more prolonged effect compared to regular insulin. | |||
==Usage== | |||
NPH insulin is often used in combination with short-acting insulins to provide both basal and prandial glucose control. It is usually administered once or twice daily, depending on the individual's needs and the regimen prescribed by a healthcare provider. | |||
== | ==Side Effects== | ||
Common side effects of NPH insulin include [[hypoglycemia]], weight gain, and injection site reactions. Hypoglycemia is the most significant risk and requires careful monitoring of blood glucose levels. | |||
==Comparison with Other Insulins== | |||
NPH insulin is one of several types of insulin used to manage diabetes. It is less expensive than some of the newer long-acting insulins, such as [[insulin glargine]] and [[insulin detemir]], but may require more frequent dosing and monitoring. | |||
== | ==Administration== | ||
NPH insulin is typically administered via subcutaneous injection using a syringe, insulin pen, or insulin pump. Proper technique and rotation of injection sites are important to minimize discomfort and prevent lipodystrophy. | |||
==Related pages== | |||
* [[Insulin therapy]] | * [[Insulin therapy]] | ||
* [[Diabetes management]] | * [[Diabetes management]] | ||
* [[Insulin | * [[Hypoglycemia]] | ||
* [[Insulin analogs]] | |||
[[Category:Insulin therapies]] | |||
[[Category:Diabetes treatments]] | |||
[[Category:Insulin]] | |||
[[Category: | |||
Latest revision as of 14:23, 21 February 2025
A type of insulin used to manage blood sugar levels in diabetes
NPH insulin (Neutral Protamine Hagedorn insulin) is an intermediate-acting insulin used in the management of diabetes mellitus. It is designed to help control blood sugar levels in individuals with type 1 diabetes and type 2 diabetes.
History[edit]
NPH insulin was developed in the 1940s by Hans Christian Hagedorn and B. Norman Jensen. The addition of protamine, a protein, to insulin extends its duration of action, making it suitable for basal insulin needs.
Pharmacology[edit]
NPH insulin is an intermediate-acting insulin with an onset of action of 1 to 2 hours, a peak effect occurring 4 to 12 hours after administration, and a duration of action of approximately 12 to 18 hours. It is typically administered subcutaneously.
Mechanism of Action[edit]
NPH insulin works by facilitating the uptake of glucose into cells, particularly in the liver, muscle, and fat tissue, thereby lowering blood glucose levels. The protamine component delays the absorption of insulin, providing a more prolonged effect compared to regular insulin.
Usage[edit]
NPH insulin is often used in combination with short-acting insulins to provide both basal and prandial glucose control. It is usually administered once or twice daily, depending on the individual's needs and the regimen prescribed by a healthcare provider.
Side Effects[edit]
Common side effects of NPH insulin include hypoglycemia, weight gain, and injection site reactions. Hypoglycemia is the most significant risk and requires careful monitoring of blood glucose levels.
Comparison with Other Insulins[edit]
NPH insulin is one of several types of insulin used to manage diabetes. It is less expensive than some of the newer long-acting insulins, such as insulin glargine and insulin detemir, but may require more frequent dosing and monitoring.
Administration[edit]
NPH insulin is typically administered via subcutaneous injection using a syringe, insulin pen, or insulin pump. Proper technique and rotation of injection sites are important to minimize discomfort and prevent lipodystrophy.
